跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
From Molecule to Medicine: The Journey a Drug Must Survive

The last two gates: approval and after

4 / 4
Approval and monitoring are easy to skip past, because no molecule is being designed or tested. But they are doing real work. Approval is a judgment made by people who did not run the trials: were the trials sound, is the benefit meaningful, are the risks acceptable for this condition? And monitoring continues afterward, because trials involve thousands of patients at most, while a drug may eventually be taken by millions. A harm that occurs in one person in ten thousand will not show up in a trial, but it will show up in the real world. So the journey does not end at approval. The evidence keeps accumulating, and a drug can be restricted or withdrawn if that evidence turns bad.
0:00 / 0:00

Regulatory approval is a review of the evidence a drug developer has assembled. Regulators examine whether the trials were run properly, whether the benefit is real and meaningful, and whether the risks are acceptable for the condition being treated. A drug for a mild condition must clear a higher safety bar than a drug for a life-threatening one, because the acceptable balance between benefit and risk depends on what is being treated. Approval is not a rubber stamp; it is a separate judgment made by people who did not run the trials.

Post-approval monitoring continues after the drug is on the market. Clinical trials involve thousands of patients at most, so harms that occur in one person in ten thousand may never appear during testing. Once a drug is prescribed widely, those rare effects can surface, and monitoring systems exist to detect them. A drug can be restricted or withdrawn after approval if new evidence shows the risks are greater than expected. This means the journey does not end at approval; the evidence base keeps growing.

Every stage in this journey is a filter. Discovery and design, preclinical testing, the three trial phases, regulatory approval, and post-approval monitoring each remove candidates that are unsafe, ineffective, or not clearly better than existing options. The stages are not bureaucratic obstacles; they are the mechanism by which medicine avoids harming people with drugs that only looked promising.

上一页4 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion